The research team led by Daniel Anderson at the Massachusetts Institute of Technology has published a research paper titled “Combinatorial development of nebulized mRNA delivery formulations for the lungs” in the journalRead More…
In recent years, messenger ribonucleic acid (mRNA) therapy has garnered significant interest and has been developed for the treatment of a range of diseases, including rare genetic disorders, neurodegenerative diseases, inflammation, cancer,Read More…
Lyme disease is the most common vector-borne infectious disease in the United States, in part because there is currently no human vaccine against it. In a recent research report titled “Development ofRead More…
On October 2, 2023, the Nobel Committee announced that this year’s Nobel Prize in Physiology or Medicine would be jointly awarded to Katalin Karikó and Drew Weissman for their discoveries in nucleosideRead More…
In a recent study, researchers from the Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania developed a proof-of-concept model for delivering gene-editing tools to treatRead More…
mRNA-based cancer therapies hold immense potential to revolutionize cancer treatment. However, there are several challenges that need to be addressed for the clinical use of mRNA in cancer therapy. mRNA itself isRead More…
Proteins in organisms are primarily composed of 20 common amino acids encoded by 61 codons. Except for methionine and tryptophan, the other amino acids are encoded by 2 to 6 different codons.Read More…
So far, over 170 types of RNA modifications have been identified, and these modifications are widely distributed in non-coding RNAs. With the advancement of detection techniques, various chemical modifications have been detectedRead More…
Multiple myeloma is an incurable bone marrow cancer that causes over 100,000 deaths annually. Known for its rapid and deadly spread, it is one of the most challenging diseases scientists face today.Read More…
International pharmaceutical giant Sanofi recently announced a $25 million investment over five years in MIT’s Daniel Anderson lab to support the development of next-generation mRNA delivery technology. The funding will be utilizedRead More…